Skip to content

PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518741-21-00
Acronym
PRODIGE 34 - ADAGE
Enrollment
973
Registered
2025-01-17
Start date
2014-12-23
Completion date
Unknown
Last updated
2025-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colon cancer

Brief summary

The primary endpoint is relapse-free survival (RFS). It is defined as the time limit between the randomisation date and the date of the first recurrence (local or remote) or the date of death, regardless of the cause. All second cancers, colon or not, shall not be taken into account. The living patients without recurrence shall be censored at the date of their last assessment.

Detailed description

The dose intensity, The overall tolerance to the treatments, The time to recurrence, Overall survival, The time to decrease in autonomy, The time to decrease in the quality of life

Interventions

Sponsors

Fondation Franc.Cancerologie Digestive
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint is relapse-free survival (RFS). It is defined as the time limit between the randomisation date and the date of the first recurrence (local or remote) or the date of death, regardless of the cause. All second cancers, colon or not, shall not be taken into account. The living patients without recurrence shall be censored at the date of their last assessment.

Secondary

MeasureTime frame
The dose intensity, The overall tolerance to the treatments, The time to recurrence, Overall survival, The time to decrease in autonomy, The time to decrease in the quality of life

Countries

Belgium, France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026